Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Forecasted to Post Q1 2023 Earnings of ($1.22) Per Share

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) – Analysts at Wedbush issued their Q1 2023 EPS estimates for Apellis Pharmaceuticals in a research note issued on Thursday, April 28th. Wedbush analyst L. Chico expects that the company will post earnings per share of ($1.22) for the quarter. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q2 2023 earnings at ($1.22) EPS, Q3 2023 earnings at ($1.14) EPS and Q4 2023 earnings at ($1.10) EPS.

A number of other research analysts have also recently issued reports on APLS. Needham & Company LLC reaffirmed a “buy” rating and issued a $70.00 price target on shares of Apellis Pharmaceuticals in a report on Friday, December 31st. Citigroup reiterated a “focus list” rating and issued a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Thursday, March 17th. JPMorgan Chase & Co. increased their price objective on shares of Apellis Pharmaceuticals from $66.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, April 4th. Roth Capital lowered shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 price objective on the stock. in a research note on Wednesday, April 13th. Finally, Robert W. Baird increased their price objective on shares of Apellis Pharmaceuticals from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $70.67.

NASDAQ APLS opened at $44.87 on Friday. The company has a fifty day simple moving average of $48.74 and a two-hundred day simple moving average of $43.77. The stock has a market cap of $4.78 billion, a P/E ratio of -5.02 and a beta of 1.61. Apellis Pharmaceuticals has a 12-month low of $27.50 and a 12-month high of $73.00. The company has a current ratio of 6.25, a quick ratio of 6.13 and a debt-to-equity ratio of 0.95.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last posted its quarterly earnings results on Monday, February 28th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.54) by ($0.07). During the same period last year, the firm earned $0.93 EPS.

Large investors have recently bought and sold shares of the company. Arizona State Retirement System lifted its stake in shares of Apellis Pharmaceuticals by 25.4% in the fourth quarter. Arizona State Retirement System now owns 20,617 shares of the company’s stock worth $975,000 after buying an additional 4,172 shares in the last quarter. Asymmetry Capital Management L.P. purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth about $6,593,000. Guggenheim Capital LLC purchased a new position in Apellis Pharmaceuticals during the third quarter worth about $1,439,000. Assenagon Asset Management S.A. purchased a new position in Apellis Pharmaceuticals during the fourth quarter worth about $3,181,000. Finally, O Shaughnessy Asset Management LLC raised its stake in Apellis Pharmaceuticals by 21.7% during the third quarter. O Shaughnessy Asset Management LLC now owns 3,006 shares of the company’s stock worth $99,000 after purchasing an additional 537 shares during the period. 82.03% of the stock is currently owned by hedge funds and other institutional investors.

In other Apellis Pharmaceuticals news, insider Lukas Scheibler sold 1,233 shares of the stock in a transaction on Monday, January 31st. The shares were sold at an average price of $38.47, for a total transaction of $47,433.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Mark Jeffrey Delong sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, April 20th. The stock was sold at an average price of $52.53, for a total transaction of $367,710.00. Following the completion of the transaction, the senior vice president now directly owns 28,481 shares in the company, valued at $1,496,106.93. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,399 shares of company stock worth $2,227,305. 9.50% of the stock is owned by company insiders.

About Apellis Pharmaceuticals (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Featured Articles

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.